Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
March 17, 2021Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …
Axol Bioscience and CENSO Biotechnologies enter merger agreement
March 17, 2021Research and Development Axol Bioscience, Censo Biotechnologies, immune cell, merger, neuroscience
Axol Bioscience, an established provider of iPSC-derived cells, media, and characterisation services, and CENSO Biotechnologies, a cell biology CRO focused …
PEP-Therapy and Institut Curie’s cancer drug trial approved in France
March 17, 2021Research and Development Cancer, France, Pep-therapy
PEP-Therapy and Institut Curie have been granted approval from the French National Agency for Medicines and Health Products (ANSM) to …
Medicago & GSK start plant-derived COVID-19 vaccine trial
March 17, 2021Research and Development COVID-19, GSK
Medicago and GSK have announced the start of Phase III clinical testing of Medicago’s plant-derived COVID-19 vaccine. The vaccine candidate …
Johnson & Johnson’s arthritis drug shows promising results in Phase III trial
March 16, 2021Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis
Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.
Roche and PTC’s SMA treatment shows positive trial results
March 16, 2021Manufacturing and Production PTC, PTC Therapeutics, Roche, sma, spinal muscular atrophy
Roche and PTC Therapeutics’s Evrysdi treatment for children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) …
AstraZeneca vaccine suspended in 11 European countries
March 16, 2021Manufacturing and Production AstraZeneca
Blood clot fears have caused 11 European countries to suspend the use of the Oxford-AstraZeneca vaccine. France, Germany, Italy, and …
Gilead and MSD partner to develop and commercialise two-drug HIV regimen
March 16, 2021Manufacturing and Production Gilead, HIV, MSD
Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …
Perception and Otsuka enter collaboration and licensing deal for depression drug candidate
March 16, 2021Manufacturing and Production CNS, Otsuka Pharmaceutical, Perception Neuroscience, depression
Perception Neuroscience and Otsuka Pharmaceutical have announced a collaboration and licensing agreement for the development and commercialisation of Perception’s lead …
Ocuphire’s pupil dilation treatment shows promising Phase III trial results
March 15, 2021Sales and Marketing Ocuphire, eye treatment, nyxol
Ocuphire Pharma’s Nyxol treatment for pharmacologically-induced pupil dilation (mydriasis) has met its primary and secondary endpoints in its Phase III …
Newron and Zambon to collaborate on Parkinson’s dyskinesia drug trial
March 15, 2021Sales and Marketing Newron Pharmaceuticals, Parkinson's, Zambon
Newron Pharmaceuticals and its partner Zambon have announced an agreement for a potentially pivotal study to evaluate the efficacy of …
Roche acquire GenMark in $1.8 billion deal
March 15, 2021Sales and Marketing Diagnostics, GenMark, Roche
Pharmaceutical giant Roche have bought GenMark Diagnostics in a deal worth $1.8 billion, expanding their infectious disease testing for illnesses …
Netherlands suspends AstraZeneca vaccine despite safety assurances
March 15, 2021Medical Communications, Sales and Marketing AstraZeneca, COVID-19, EMA, EU, WHO
The Netherlands has become the latest country to suspend the use of the Oxford-AstraZeneca vaccine amid concerns it may cause …
Phase III trial of Libtayo stopped early after positive overall survival results
March 15, 2021Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi
A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …
Pharmafile.com’s top 10 news stories of the week
March 12, 2021Medical Communications COVID-19, covid 19 news, covid-19 news, news, news roundup, pharma news
In the last week, a number of new treatment developments have made the news; for COVID-19, GSK and Vir’s monoclonal-antibody …
Kintor’s COVID-19 treatment reduces mortality by 92%
March 12, 2021Medical Communications Brazil, Brazil variant, COVID-19, Kintor, covid-19 treatment
Kintor Pharmaceutical’s Proxalutamide treatment has been proven to reduce risk of mortality from COVID-19 by 92%, in a clinical trial …
J&J’s one-shot COVID-19 vaccine approved by European Commission
March 12, 2021Medical Communications COVID-19, EMA, Johnson & Johnson
The European Commission has granted Johnson and Johnson’s single-shot COVID-19 vaccine Conditional Marketing Authorisation (CMA), it was announced on Thursday. …
Novavax announces vaccine’s high efficacy against original and variant COVID-19 strains
March 12, 2021Medical Communications COVID-19, Novavax, vaccines
Novavax has announced final efficacy of 96.4% against mild, moderate, and severe disease caused by the original COVID-19 strain in …
Altimmune expands COVID-19 vaccine manufacturing deal with Lonza
March 12, 2021Medical Communications Altimmune, COVID-19, Lonza, vaccines
Altimmune has expanded its previously-announced AdCOVID vaccine manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated …
Eli Lilly’s COVID-19 treatment combination 87% effective in Phase III trial
March 11, 2021COVID-19, Eli Lilly, covid-19 treatment
Eli Lilly has shown positive results in its Phase III combination drug trial, which reduced hospitalisations and deaths related to …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
